ZEISS India Strengthens Portfolio with the Launch of ZEISS ClearMind Lenses

▴ ZEISS India
Introducing are first-of-its-kind ZEISS prescription lenses to provide extremely clear vision designed to reduce cognitive load.

National, 1st April: ZEISS, a pioneer of science in optics announces the launch its latest prescription lenses ZEISS ClearMind lenses in India. The all-day lenses addition to the lens portfolio delivers clear vision while reducing cognitive load due to blur for daily eyeglass wearers. For eye care professionals this offering elevates their practice with advanced lens technology that supports both visual performance and comfort.

 

In today’s fast-paced world with countless visual stimuli to process, there is an increase in information overload where individuals may feel overwhelmed. With pre-existing conditions of blur on spectacle lenses, the ability to identify and interpret complex stimuli is compromised. ZEISS ClearMind lenses are built on a unique design that reduces and smooths optical errors, increasing the clear vision zones and reducing peripheral lens blur thus reducing cognitive load.

 

Commenting on the addition to the lens portfolio, Rohan Paul, Business Head – India & Neighboring Markets, Vision Care, ZEISS India, said, “At ZEISS, innovation is at the core of everything we do. We are committed to protecting vision & visual health of world’s consumers. The launch of ZEISS ClearMind lenses reflects our continued focus on developing advanced optical solutions that enable individuals to see better, clearer and experience better comfort in their daily lives. We look forward to the positive impact these lenses will have, in collaboration with our valued business partners, as we continue to reach individuals seeking effective and personalized eye care solutions.”

 

Benefits of ZEISS ClearMind lenses at a glance

  • ZEISS ClearMind is a new, premium, all-day lens portfolio with larger zones of clear vision  embedded with ZEISS NeurOptix technology
  • In consumer studies, 96 % of wearers confirmed extremely clear vision. 9 out of 10 wearers also experienced less cognitive load in a blind test compared to a standard ZEISS progressive lens
  • The lenses are available for all age groups to promote perceived overall well-being, and good vision

 

Backed by scientific research to reduce cognitive load

Research conducted at the ZEISS Vision Science Lab (Tübingen University, Germany) established a direct connection between lens-induced blur and increased cognitive load. In consumer studies, 96% of wearers reported extremely clear vision when using ZEISS ClearMind lenses. 9 out of 10 wearers experienced reduced cognitive load compared to standard progressive lenses. Many wearers also reported an improvement in overall well-being while using the lenses. They also highlighted the importance of comfortable vision while staying focused for long hours.

 

 

Embedded with ZEISS NeurOptix technology for improved visual clarity

By aligning lens clarity zones to natural eye-movement patterns, ZEISS NeurOptix technology aims to reduce the brain’s cognitive load, provide more relaxed, effortless vision, as well as improve comfort during long days of digital, visually busy and dynamic activity. As a result, ZEISS Progressive ClearMind lenses offer up to 41% larger near-vision zones compared to ZEISS SmartLife progressive lenses. The technology also supports fast adaptation. 88% of wearers adjust within a few days, and over half within just an hour.

 

All-day lens portfolio includes single vision, progressive and digital focal types

ZEISS Single Vision ClearMind lenses are designed for 18+ wearers with blurry vision near or far. They reduce peripheral blur and provide larger clear vision zones than standard ZEISS lenses. ZEISS Digital ClearMind lenses are made for 35+ wearers experiencing blurry vision and tired eyes. They reduce blur and offer larger vision zones than ZEISS Digital SmartLife lenses. The design supports natural viewing habits and ensures smooth transition to near vision. It also enables an easier shift to progressive lenses in the future. ZEISS Progressive ClearMind lenses are designed for 45+ wearers with presbyopia. They reduce and optimize peripheral blur, creating wider clear vision zones than ZEISS SmartLife progressive lenses. They support smooth transitions across distances and improve overall visual flow.

 

For more details on ZEISS ClearMind lenses, Please visit ZEISS ClearMind At a Glance

About ZEISS Group:

ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling 12 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets.

 

For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.

 

With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.

 

With around 46,600 employees, ZEISS is active globally in almost 50 countries with around 30 production sites, 60 sales and service companies and 27 research and development facilities. Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Fortis Escorts Faridabad Launches ‘Sehat Express’ Mobile Bus for Accessible Doorstep Cancer Screening in association with Faridabad Industries Association Charitable Society and Rotary Club FaridabadOctober 05, 2026
Advanced Thrombectomy Saves 60-Year-Old Woman After Severe Heart Attack at KIMS SaveeraOctober 05, 2026
Constipation, Bloating and Long Sitting Hours: Doctors at RG Hospitals Delhi Warn Urban Professionals Not to Ignore Gut ProblemsOctober 05, 2026
Fermenta – Centre of Excellence for Food Fortification Inaugurated at NIFTEM-T, ThanjavurOctober 05, 2026
Alzheimer’s Dementia: Recognising the Signs, Diagnosing Earlier and Changing the Future of Brain HealthOctober 05, 2026
Man Matters Hairfall Case Study 2026: 7 Lakh+ Consultations Reveal How Hair Loss Changes With AgeOctober 05, 2026
Medication Reconciliation: A System-Level Step for Safer Transitions of CareOctober 05, 2026
The Role of Clinical Pharmacists in Safer Medication UseOctober 05, 2026
Nanavati Max Hospital Hosts Max Cancer Congress 2026, Bringing Together Oncology Experts to Explore the Future of Cancer Care October 01, 2026
Dhiya Fertility and Maternity Center Performs Tamil Nadu’s First Robot-Assisted Fertility Procedure; 37-Year-Old Woman Delivers Healthy Baby GirlOctober 01, 2026
Habuild’s “Are You Still Awake?” Campaign Encourages India to Switch Off, Sleep on Time and Not Take Everything to Heart October 01, 2026
CoinSwitch Turns Profitable in FY26 as Revenue Surges 150% to ₹324 CrOctober 01, 2026
Mega CPR Training: Baby Memorial Hospital Vadakara enters Asia and India Book of RecordsOctober 01, 2026
Supertails vaccinates 300 dogs and cats against rabies across Bengaluru in a three-day World Rabies Day drive October 01, 2026
Why Continuity of Care Matters When Patients Move Between Health FacilitiesOctober 01, 2026
Building Stronger Referral Pathways Between Primary Care and Specialist ServicesOctober 01, 2026
How Can Diabetes and High Blood Pressure Quietly Lead to Kidney Failure?September 30, 2026
Apollo Hospitals’ “My Hands Are Ready” Sets World Record Title with 61,221 CPR Pledges in 30 DaysSeptember 30, 2026
How Medical Device Trials and Validation Shape Safer Healthcare Innovation in IndiaSeptember 30, 2026
Medical Device Safety in India: What Patients Should Know About Recalls and AlertsSeptember 30, 2026